Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2023 Industry Snapshot
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 MA Life Sciences Workforce Analysis Report
    • 2021 State of Diversity, Equity, & Inclusion Report
    • Economic Development
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Astrocyte Pharmaceuticals, Inc.

Life Sciences | Drug Development
Cambridge, MA 617-444-8765 Website

Overview

Astrocyte Pharmaceuticals Inc. is a new drug development company dedicated to clinically proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury patients.

Astrocyte Pharmaceuticals is developing a proprietary small molecule pharmaceutical agent for acute administration to patients who have suffered a TBI, concussion or stroke. This product would be administered by intravenous injection by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death. Our approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts as we focus on a non-neuronal cell type, astrocytes, which are the most common cell type in the human brain and have only recently received broader attention as important cellular targets for therapeutic research. Additionally, as astrocytes are the natural caretaker cells in the brain and their activation, as our data show, enhances multiple natural healing mechanisms including protection against edema, glutamate excitotoxicity and oxidative stress

Company News

News

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

May 03, 2021

Posted by Astrocyte Pharmaceuticals, Inc.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2023 All Rights Reserved